Showing posts with label Research News. Show all posts
Showing posts with label Research News. Show all posts

30/09/2012

XMRV Update


It now seems almost certain that Xenotropic Murine-Leukaemia Retrovirus (XMRV) is not linked to ME. Researchers at the Whittemore Peterson Institute in 2009 were thought to have discovered XMRV in the blood of people with ME; however, most of the research done since then, including a comprehensive study concluded in 2012, has failed to find it. There are still some queries hanging over the issue (for instance no-one has adequately explained the results of the research in 2010 which found other Human Gamma Retroviruses (HGRVs) in the blood of people with ME), but it's now generally agreed that the original results were due to contamination.

There's a very good, comprehensive article about XMRV/HGRV research on the ME Research UK website, and a basic update about the 2012 study on the ME Association (MEA) website.

As the MEA point out, the lack of a link between XMRV and ME does not mean that ME is not caused by a virus or indeed by a retrovirus: it means that it is still not known what causes ME. It is known, however, that in most cases ME is triggered by a virus (ie people tend to develop ME following a viral infection such as 'flu, glandular fever, or hepatitis), and it is quite likely that it has a viral origin. Articles in the press which suggest that because ME is not caused by XMRV it therefore follows that it must not be a biomedical disease at all are misunderstanding or misrepresenting the recent study, and displaying a very poor grasp of science and a distinct lack of knowledge of other research in the field.

Note: I have deleted my original article about XMRV because the information in it was out of date and could have been confusing.

30/07/2012

Call For Research


The Medical Research Council (in the UK) are asking for more bids for research into ME, specifically in these areas:
  • Immune disregulation
  • Pain (headache, facial pain, and myalgia)
  • Improved sub-phenotyping and stratification of ME
  • ME in children
  • Neuropathology (inflamation of brain and spinal cord)
There are more details on the ME Association website

30/06/2012

Immunology


The annual international conference organised by Invest In ME in 2012 focused on the role of the immune system in ME, and asked the question "is ME an autoimmune disorder?". There is certainly evidence of immunological dysfunction in people with ME, and several current research projects are focusing on this area. There is a detailed report on the papers presented at the conference on the Invest in ME website.

30/05/2012

Biobank


A Biobank has been set up with funding from ME Research UK, Action for ME, the ME Association, and a private donor. Researchers from the London School of Hygiene and Tropical Medicine are taking blood samples from people who have been diagnosed with ME, including some who are severely affected. The blood will be stored at the Royal Free Hospital and used by various research projects.

There is further information on the ME Research UK website (warning to the squeamish: this features a picture of a blood test).

30/12/2011

Rituximab


In October 2011 Norweigan researchers published in the journal PLOS ONE the results of a double-blind placebo-controlled trial of the anti-cancer drug Rituximab on a small group of ME patients.

Two-thirds of the patients receiving the Rituximab (as opposed to 13% of those receiving the placebo) saw an overall improvement in their health, and none reported serious adverse side effects. As the improvement affected all ME symptoms, the researchers believe the drug may touch the central mechanism of the condition. The responses are consistent with the theory that ME is an autoimmune disease.

As this was only a small initial study, a great deal more research needs to be done before it is known whether Rituximab would be consistently both helpful and safe for ME patients in general. However, the researchers have now been given a grant from the Norweigan government to help fund an expanded study.

30/06/2011

A Case For Clinical Trials


The 2011 Invest in ME conference A Way Forward For ME - A Case For Clinical Trials featured a selection of international speakers, each focusing on a different area of research. Topics covered included the question of whether ME is an autoimmune or an infectious illness, the study of proteins in the spinal fluid of patients, and the link between the brain and the gastrointestinal tract.

A detailed report is available on the Invest in ME website.

30/04/2011

Spinal Fluid


A study published in the journal PLOS ONE in February 2011 analysed the spinal fluid of people with ME and people with post-treatment Lyme Disease (the symptoms of which are similar to those of ME), compared with that of healthy controls. Researchers found hundreds of proteins which were specific to each illness, and which differed from those found in the healthy people. Further research needs to be done, but it is thought that the findings could eventually lead to diagnostic tests for both conditions.

30/03/2011

PACE Trial


In February 2011 the results of the PACE trial were published in the Lancet. The trial set out to study the effects of three therapies on people with CFS: graded exercise therapy (GET), cognitive behavioural therapy (CBT), and adaptive pacing technique (APT), compared with specialist medical care. It concluded that GET and CBT were moderately helpful and that APT was not. This was hardly ground-breaking, as CBT and GET are merely coping strategies, which should be moderately helpful to anyone with any physical illness, if applied within the patient's own limitations: the researchers would have reached the same conclusions if they had been studying cancer, for instance.

From the point of view of ME patients and specialists however, the PACE trial had several flaws. Firstly the diagnostic criteria used to select participants was a general and very basic one for chronic fatigue, which meant that the study included people with a range of other fatigue-based conditions, including psychological ones. Secondly the study involved travel and exercise, which meant that most people with ME and anyone with severe ME would have been unable or unwilling to take part. And thirdly the researchers did not study the pacing technique used by the majority of people with ME, but a technique of their own which was invented solely for the trial, meaning that the results for this part of the trial were meaningless as a test for pacing per se.

Unfortunately, the results of the trial were widely misunderstood and misreported by the media. As well as confusing ME and the wider range of chronic fatigue states actually studied, reporters ignored the trial's recommendation that further research is needed into better treatments, and demonstrated a fundamental lack of understanding of the difference between GET and just going to the gym. This resulted in inaccurate and potentially dangerous headlines such as "exercise cures ME", and led the ME Association to make a formal complaint to the Science Media Centre.

In fact, the defining symptom of ME is post-exertional neuro-immune exhaustion, which means that exercise makes people with ME worse. Patient surveys indicate that GET is often harmful to people with ME as it is generally not applied within the patient's own limitations.

Action for ME's response to the PACE trail is here, and the ME Association's response is here.